Scarica l'app Stockscreener
18.66
0.53%
-0.10
Precedente Chiudi:
$18.76
Aprire:
$18.87
Volume 24 ore:
990.27K
Relative Volume:
0.30
Capitalizzazione di mercato:
$1.56B
Reddito:
-
Utile/perdita netta:
$-27.03M
Rapporto P/E:
-33.32
EPS:
-0.56
Flusso di cassa netto:
$-23.97M
1 W Prestazione:
-8.80%
1M Prestazione:
+187.08%
6M Prestazione:
+273.20%
1 anno Prestazione:
+279.27%
Intervallo 1D:
$18.59
$19.98
Intervallo di 1 settimana:
$18.50
$21.57
Portata 52W:
$2.54
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Nome
Corvus Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 900-4520
Indirizzo
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
18.66 | 1.57B | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-01-02 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-18 | Iniziato | Oppenheimer | Outperform |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-05-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Downgrade | Mizuho | Buy → Neutral |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-05-29 | Iniziato | ROTH Capital | Buy |
| 2017-08-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Iniziato | Credit Suisse | Outperform |
| 2016-04-18 | Iniziato | Guggenheim | Buy |
Mostra tutto
Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie
Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge - Sahm
Corvus Pharmaceuticals (CRVS) price target increased by 128.26% to 35.70 - MSN
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data - AOL.com
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - Investing.com
Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options - Nasdaq
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - The Globe and Mail
CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Momentum - Sahm
Mizuho Raises Price Target on Corvus Pharmaceuticals to $30 From $20, Keeps Outperform Rating - marketscreener.com
Corvus Soquelitinib Data Spurs Phase 2 Plans And Fuels CRVS Reassessment - Sahm
Aug Selloffs: Why is Corvus Pharmaceuticals Inc. stock going downJuly 2025 Price Swings & Accurate Entry/Exit Alerts - mfd.ru
Will Corvus Pharmaceuticals Inc. benefit from rate cutsPrice Action & Low Risk Growth Stock Ideas - mfd.ru
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet - Your Wyoming Link
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know - Yahoo Finance
10 Big Names Stumbling Hard - Insider Monkey
Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump - Finviz
If You Invested $1000 In Corvus Pharma Stock 5 Years Ago, You Would Have This Much Today - Sahm
Latham Watkins Advises Corvus Pharmaceuticals in Upsized Public Offering of Common Stock - Latham & Watkins LLP
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 9.3%Here's What Happened - MarketBeat
Hedge Fund Moves: Is Corvus Pharmaceuticals Inc exposed to political risk2025 Technical Overview & Consistent Income Trade Recommendations - baoquankhu1.vn
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study - Finviz
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans - Yahoo Finance
Corvus Pharmaceuticals (CRVS) Valuation Check After Positive Soquelitinib Data And Equity Raise - Sahm
What's Driving the Market Sentiment Around Corvus Pharmaceuticals Inc? - Sahm
Corvus Pharmaceuticals raises $201.2 million in upsized public offering By Investing.com - Investing.com South Africa
Corvus rally continues as clinical optimism offsets dilution concerns - Mugglehead Investment Magazine
Corvus Pharmaceuticals raises $201.2 million in upsized public offering - Investing.com
Corvus Pharmaceuticals Closes Upsized Public Offering, Raising Approximately $201.2 Million - Quiver Quantitative
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - The Manila Times
Corvus Pharma raises $201M to support cancer and skin trials - stocktitan.net
Cantor Fitzgerald reiterates Overweight rating on Corvus Pharmaceuticals stock By Investing.com - Investing.com Canada
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results - Finviz
Corvus Pharmaceuticals - The Pharma Letter
Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering - TipRanks
Corvus Pharmaceuticals Announces Public Offering of Common Stock - TradingView
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains - MarketBeat
10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Are Hitting New Highs - Insider Monkey
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat
Jefferies raises Corvus Pharmaceuticals stock price target to $42 on strong AD data - Investing.com Canada
Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies - TipRanks
Corvus Pharmaceuticals prices upsized public offering at $22.15 per share By Investing.com - Investing.com Australia
Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights
Corvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15 - MSN
Corvus Pharmaceuticals Prices Upsized Public Stock Offering - Eudaimonia and Co
Corvus Pharmaceuticals stock hits all-time high at 22.22 USD By Investing.com - Investing.com Nigeria
CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million - Stocktwits
Corvus Pharmaceuticals launches $150 million public offering By Investing.com - Investing.com India
Corvus Pharma raises $175M to advance lymphoma and atopic dermatitis trials - Stock Titan
Corvus Pharmaceuticals Prices $175M Upsized Public Offering to Fund Clinical Trials - Intellectia AI
Corvus Pharmaceuticals prices upsized public offering at $22.15 per share - Investing.com
Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):